Aberrant expression of TOPBP1 has been observed in multiple malignancies, including breast, ovarian, lung, and colorectal tumors, and high TOPBP1 expression is correlated with poor prognosis and breast tumor aggressiveness (30–34), suggesting its potential as a tumor-promoting or prognostic marker. Here, TOPBP1 is linked to neoplasm.